abstract |
A method for assessing the state of Alzheimer's disease in patients is disclosed. A method for monitoring the progression of Alzheimer's disease in patients is also disclosed. The method applies detection of specific markers in body fluids (e.g. CSF), using mass spectrometric analysis (SELDI-TOF MS). The specific markers are: human cystatin C, human beta-2-microglobulin, human myoglobin neurosecretory protein VGF or fragments of these proteins. |